Proactive Investors - Run By Investors For Investors

Nuvectra wounded after 1Q earnings miss, FDA application delay

The neurostimulation medical-device company posted a wider loss than analysts had expected
neurons
Revenue from Algovita, the company’s flagship spinal cord stimulation system, increased 22% year-over-year to $11 million

Nuvectra Corp (NASDAQ:NVTR), a neurostimulation medical-device company, reported a first-quarter loss late Wednesday that was wider than Street expectations.

The company posted a net loss of $0.83 per share on revenue of $11.1 million, while analysts expected a $0.66 loss on $12 million in revenue.

Shares collapsed 30% to $6.55 Thursday afternoon.

Revenue from Algovita, the company’s flagship spinal cord stimulation system, increased 22% year over year to $11 million.

“Our primary focus remains on advancing Algovita to deliver stronger results through the duration of 2019,” CEO Fred Parks said. “We are continuing to drive our clinical efforts, accelerating productivity, and increasing our sales force from approximately 60 territories as of May 1, 2019 to approximately 75 by year end. Therefore, we are introducing full year 2019 Algovita revenue guidance of $57-62 million.”

The Plano, Texas company also announced it was providing additional information to the FDA regarding its premarket approval application for Virtis, its sacral nerve stimulation treatment for chronic urinary retention.

It expects to submit the information near the end of 2019, pushing back potential approval to early 2020.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full NVTR profile View Profile

Nuvectra Corp Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use